Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin In Dravet Syndrome; First Sites Activated With A Number Of Additional Rapid-Start Sites Being Activated In The Coming Weeks
Celldex Therapeutics Presents 52-Week Results From Barzolvolimab Phase 2 Study In Chronic Spontaneous Urticaria At EADV 2024; 71% Of Patients Achieved Complete Response At Week 52; Rapid, Profound And Durable Improvement In UAS7 As Early As Week 1...
EXCLUSIVE: Ideal Power Partners With Sekorm, Driving Expansion in China's Semiconductor Market
Maxim Group Initiates Coverage On Nutex Health With Buy Rating, Announces Price Target of $45
Wall Street Eyes Strong Finish To The Week Despite Futures Suggesting Moderation In Tech Buying: Strategist Cautions Against Factoring Rapid, Steep Cuts Ahead Of Next Week's Fed Meeting
Matrix Service Company (MTRX) Q4 2024 Earnings Call Transcript Summary